Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE

(GSK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

GlaxoSmithKline to Sell Two Former Novartis Vaccines for up to EUR955 Million

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/21/2019 | 03:58am EST
Stocks mentioned in the article
ChangeLast1st jan.
BAVARIAN NORDIC A/S -0.09% 164 Delayed Quote.27.19%
GLAXOSMITHKLINE -0.92% 1705.2 Delayed Quote.16.64%
NOVARTIS -0.32% 88.49 Delayed Quote.19.53%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
08:12aGLAXOSMITHKLINE : Nucala is the first treatment to show a significant reduction ..
AQ
04:09aLONDON STOCK EXCHANGE : FTSE inches lower as 3i drop offsets Burberry surge
RE
03:43aMerck KGaA raises 2019 guidance after Versum takeover
RE
11/14GLAXOSMITHKLINE : Ex-dividend day for interim dividend
FA
11/11ANDREW WITTY : UnitedHealth Group Names Andrew Witty as President
DJ
11/07GLAXOSMITHKLINE : EACS 2019 ViiV Healthcare to present 17 abstracts from its por..
AQ
10/31UK's winter election - What's in it for markets?
RE
10/30LONDON STOCK EXCHANGE : Pharma stocks lift FTSE 100 out of red
RE
10/30GLOBAL MARKETS LIVE : PSA, Fiat Chrysler, Macquarie, WhatsApp…
10/30GSK raises profit forecast after shingles vaccine sales boost
RE
More news
Financials (GBP)
Sales 2019 33 385 M
EBIT 2019 9 007 M
Net income 2019 4 388 M
Debt 2019 24 564 M
Yield 2019 4,60%
P/E ratio 2019 19,1x
P/E ratio 2020 16,0x
EV / Sales2019 3,31x
EV / Sales2020 3,08x
Capitalization 86 084 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 1 805,27  GBp
Last Close Price 1 739,40  GBp
Spread / Highest target 26,5%
Spread / Average Target 3,79%
Spread / Lowest Target -13,2%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE16.64%110 574
JOHNSON & JOHNSON1.78%345 486
ROCHE HOLDING AG22.47%257 315
MERCK AND COMPANY11.01%215 950
NOVARTIS19.53%203 065
PFIZER-16.15%202 549